# Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

> **NCT00836927** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 7 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Ridaforolimus Tablet
- **DRUG:** Ridaforolimus Intravenous (IV) Infusion

## Key facts

- **NCT ID:** NCT00836927
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02-01
- **Primary completion:** 2017-04-03
- **Final completion:** 2018-02-04
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836927, "Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00836927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*